Max Schottelius: Pioneer in Pheochromocytoma

Bausch, Birke; Tischler, Arthur S.; Schmid, Kurt Werner; Leijon, Helena; Eng, Charis; Neumann, Hartmut P. H.

doi:10.1210/js.2017-00208

Cited by 14 publications

(9 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first histologically proven case of pheo has been diagnosed by Felix Fraenkel at the University of Freiburg, Germany (Bausch et al 2017). He was a clinician who described what would be considered the classical signs and symptoms of pheochromocytoma in a young woman with bilateral adrenal tumors.…”

Section: Historymentioning

confidence: 99%

“…He was a clinician who described what would be considered the classical signs and symptoms of pheochromocytoma in a young woman with bilateral adrenal tumors. His colleague and Professor of Pathology, Max Schottelius, performed the histological investigation and he was the first who noticed that when the tumor was fixed in Mueller's solution, which contained chromate, was a "reddish grey" in color when fresh and became brown in Mueller's solution (Bausch et al 2017;Turchini et al 2018).…”

Section: Historymentioning

confidence: 99%

See 1 more Smart Citation

Pheochromocytoma

Farrugia¹,

Anestis

2019

Endocrine Regulations

View full text Add to dashboard Cite

Pheochromocytomas are rare tumors originating in the adrenal medulla. They may be sporadic or in the context of a hereditary syndrome. A considerable number of pheochromocytomas carry germline or somatic gene mutations, which are inherited in the autosomal dominant way. All patients should undergo genetic testing. Symptoms are due to catecholamines over production or to a mass effect. Diagnosis is confirmed by raised plasma or urine metanephrines or normetanephrines. Radiology assists in the tumor location and any local invasion or metastasis. All the patients should have preoperative preparation with α-blockers and/or other medications to control hypertension, arrhythmia, and volume expansion. Surgery is the definitive treatment. Follow up should be life-long.

show abstract

Section: Historymentioning

confidence: 99%

Section: Historymentioning

confidence: 99%

Pheochromocytoma

Farrugia¹,

Anestis

2019

Endocrine Regulations

View full text Add to dashboard Cite

show abstract

“…The word pheochromocytoma is of Greek origin, but its usage only dates back to 1912 (Pick 1912). The last syllables cytoma means growing cells or tumor, the middle syllables chromo refer to the former usage of a special chromate-containing stain and pheo refers to the classic brown appearance after exposure to chromate staining (Bausch et al 2017b). In contrast, paraganglioma is a terminology of pathoanatomy, meaning a tumor of the paraganglia, which are formed by the aggregation of the cell nuclei of the widespread autonomic nervous system, of which the adrenal medulla is the largest.…”

Section: Terminology and Clinical Characteristics Of Tumors Of The 'Pmentioning

confidence: 99%

65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma

Neumann¹,

Young²,

Krauß³

et al. 2018

Endocrine-Related Cancer

Self Cite

View full text Add to dashboard Cite

Although the authors of the present review have contributed to genetic discoveries in the field of pheochromocytoma research, we can legitimately ask whether these advances have led to improvements in the diagnosis and management of patients with pheochromocytoma. The answer to this question is an emphatic ! In the field of molecular genetics, the well-established axiom that familial (genetic) pheochromocytoma represents 10% of all cases has been overturned, with>35% of cases now attributable to germline disease-causing mutations. Furthermore, genetic pheochromocytoma can now be grouped into five different clinical presentation types in the context of the ten known susceptibility genes for pheochromocytoma-associated syndromes. We now have the tools to diagnose patients with genetic pheochromocytoma, identify germline mutation carriers and to offer gene-informed medical management including enhanced surveillance and prevention. Clinically, we now treat an entire family of tumors of the paraganglia, with the exact phenotype varying by specific gene. In terms of detection and classification, simultaneous advances in biochemical detection and imaging localization have taken place, and the histopathology of the paraganglioma tumor family has been revised by immunohistochemical-genetic classification by gene-specific antibody immunohistochemistry. Treatment options have also been substantially enriched by the application of minimally invasive and adrenal-sparing surgery. Finally and most importantly, it is now widely recognized that patients with genetic pheochromocytoma/paraganglioma syndromes should be treated in specialized centers dedicated to the diagnosis, treatment and surveillance of this rare neoplasm.

show abstract

“…The clinical and morphological findings of pheochromocytoma were first described in a 18 year old female patient with bilateral adrenal masses in 1886 by a German physician, Felix Fränkel [3]. Dr. Fränkel's patient died suddenly and his description of the account was consistent with hypertensive crisis and myocardial infarction [4]. Dr. Fränkel postulated that the tumor secreted a substance into the veins causing the sequelae that were observed [3].…”

Section: Introductionmentioning

confidence: 99%

“…Autopsy and histological analysis were performed by Rudolf Maier and Max Schottelius, respectively. Dr. Schottelius was credited with the first histopathological description of pheochromocytoma [4]. Over ten years following the first case report of pheochromocytoma, Moore at University College London characterized the physical and biochemical properties of adrenal extract and laid the platform for purification of the active substance [5], which was first successfully performed independently by John Abel in 1899 at Johns Hopkins University [6], and by the Japanese scientist Jokichi Takamine.…”

Section: Introductionmentioning

confidence: 99%

Precision Surgery for Pheochromocytomas and Paragangliomas

2019

View full text Add to dashboard Cite

Since Felix Fränkel’s account of pheochromocytoma in 1886, great discoveries and vast advancements in the diagnosis, genetics, anatomical and functional imaging techniques, and surgical management of pheochromcytoma and paraganglioma (P-PGL) have been made. The improved insight in the pathophysiology of P-PGL and more accurate detection methods enable physicians to tailor the treatment plan to an individual based on the genetic profile and tumor behavior. This review will cover briefly the clinical features, diagnosis, genetic mutations, and imaging modalities that are used to guide current surgical management of these rare and interesting endocrinopathies.

show abstract

Max Schottelius: Pioneer in Pheochromocytoma

Cited by 14 publications

References 11 publications

Pheochromocytoma

Pheochromocytoma

65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma

Precision Surgery for Pheochromocytomas and Paragangliomas

Contact Info

Product

Resources

About